Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21037755 | 0.83 | GAA (0.59) | GAASMN1; SMN2SPRPIK3CDMEN1 | |
| SCHEMBL30146873 | 0.78 | PIK3CD (0.38) | GAASMN1; SMN2SPRPIK3CDMEN1 | |
| SCHEMBL30146858 | 0.78 | PIK3CD (0.38) | GAASMN1; SMN2SPRPIK3CDMEN1 | |
| SCHEMBL18711313 | 0.77 | SPR (0.47) | GAASMN1; SMN2SPRKMT2A | |
| SCHEMBL17963421 | 0.77 | GAA (0.69) | GAASMN1; SMN2NR3C1PIK3CDMEN1 | |
| SCHEMBL18711320 | 0.75 | SPR (0.46) | GAASMN1; SMN2SPRKMT2A | |
| SCHEMBL21023948 | 0.72 | NR3C1 (0.38) | GAANR3C1OGAPIK3CDHRH3 | |
| SCHEMBL18965036 | 0.71 | OGA (0.40) | NR3C1OGAHRH3L3MBTL1 | |
| SCHEMBL19954641 | 0.70 | NR3C1 (0.35) | NR3C1OGAHRH3L3MBTL1 | |
| SCHEMBL23036782 | 0.70 | MEN1 (0.33) | GAASMN1; SMN2SPRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190161499-A1 | PESTICIDALLY ACTIVE 1,2,4-TRIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161499-A1 | PESTICIDALLY ACTIVE 1,2,4-TRIAZOLE DERIVATIVES | ACHE, AADAC, ATL3 | GAA 769/4885SMN1; SMN2 2530/4885NR3C1 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.